Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a shorter radiation course for prostate cancer be just as safe?

NCT ID NCT05820633

Disease control Sponsor: CHU de Quebec-Universite Laval Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 3 trial compares a new, shorter course of radiation (ultra-hypofractionated) to the standard longer course for men with prostate cancer that has spread to lymph nodes. Both groups also receive a brachytherapy boost and hormone therapy. The study aims to see if the shorter treatment causes similar side effects and maintains quality of life. 500 participants are planned, but the trial is currently suspended.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Radiotherapy (ultra-hypofractionated pelvic IMRT with HDR brachytherapy boost)
What this could lead to
If successful, this could show that a shorter course of radiation is just as safe and effective as the standard longer course for prostate cancer patients.
What could go wrong
This trial is currently suspended, so results may be delayed or not happen. It is a non-inferiority study, meaning it aims to prove the new approach is not worse than the standard, not necessarily better. Side effects from radiation remain a risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2022

Expected to finish

Dec 2035

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 95 years

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histopathologically confirmed adenocarcinoma of the prostate. * All clinical stages with lymph node involvement risk needing pelvis RT. * Stage Mx or M0. * Unfavorable Intermediate, high or very high-risk disease according to NCCN guidelines. * Having the ability to give free and informed consent. Exclusion Criteria: * Clinical stage M1. * IPSS Score \> 20 with alpha-blocking medication. * Prior pelvic radiotherapy, * History of active collagenosis (Lupus, Scleroderma, Dermatomyositis). * Past history of Inflammatory Bowell Disease. * Bilateral hip prosthesis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Node; prostate are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer prostate neoplasm radiation injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Node; prostate Prostate cancer Radiotherapy side effect

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • BC Cancer Sindi Ahluwalia centre for the Southern Interior

    Kelowna, British Columbia, V1Y 5L3, Canada

  • CHU de Québec - Université Laval

    Québec, G1R 2J6, Canada

  • CISSS de Laval, Hôpital de la Cité-de-la-Santé

    Laval, Quebec, H7M 3L9, Canada

  • CISSS de l'Outaouais, Hôpital de Gatineau

    Gatineau, Quebec, J8P 7H2, Canada

  • CISSS de la Montérégie-Centre, Hôpital Charles-Le Moyne

    Longueuil, Quebec, J4V 2H1, Canada

  • CIUSSS de l'Est-de-l'Île-de-Montréal, Hôpital Maisonneuve-Rosemont

    Montreal East, Quebec, H1T 2M4, Canada

  • CIUSSS de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke (CHUS)

    Sherbrooke, Quebec, Canada

  • CIUSSS du Centre-Ouest-de-l'Île-de-Montréal, Jewish General Hospital

    Montreal, Quebec, H3T 1E2, Canada

  • Carlo Fidani Peel Regional Cancer Centre

    Mississauga, Ontario, L5M 2N1, Canada

  • Cedars Cancer Centre, McGill University Health Centre (MUHC)

    Montreal, Quebec, H4A 3J1, Canada

  • Lakeridge Health Oshawa Cancer centre

    Oshawa, Ontario, L1G 2B9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.